Selective iron chelation in Friedreich ataxia: Biologic and clinical implications

Blood

Volumn 110, Issue 1, 2007, Pages 401-408

  Boddaert, Nathalie ^a   Sang, Kim Hanh Le Quan ^b   Rötig, Agnès ^b   Leroy Willig, Anne ^c   Gallet, Serge ^d   Brunelle, Francis ^a   Sidi, Daniel ^a   Thalabard, Jean Christophe ^b   Munnich, Arnold ^b   Cabantchik, Z Ioav ^e  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Clinique de Genetique Medicale   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Montluçon Hospital   (France)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE PLUS PROGUANIL; DEFERIPRONE; IDEBENONE; IRON CHELATING AGENT;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTICLE; ATAXIA; BIOACCUMULATION; BLOOD TOXICITY; BRAIN LEVEL; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENTATE NUCLEUS; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EYE MOVEMENT; FATIGUE; FEMALE; FRIEDREICH ATAXIA; GUILLAIN BARRE SYNDROME; HEAD MOVEMENT; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; MALE; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NEUROIMAGING; NEUROPATHY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

EID: 34347370842     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-065433     Document Type: Article

References (59)

1. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. In: Hematology: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2001: 47-61.
2. Glickstein H, Ben El R, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195-3203.
3. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
4. Heeney MM, Andrews NC. Iron homeostasis and inherited iron overload disorders: an overview. Hematol Oncol Clin North Am. 2004;18:379-403.
5. Pandolfo M. Friedreich ataxia. Semin Pediatr Neurol. 2003;10:163-172.
6. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423-1427.
7. Gakh O, Park S, Liu G, et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet. 2006;15:467-479.
8. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215-217.
9. Delatycki MB, Camakaris J, Brooks H, et al. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol. 1999;45:673-675.
10. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol. 1999;46:123-125.
11. Honda K, Casadesus G, Peterson RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci. 2004;1012:179-182.
12. Götz M, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci. 2004;1012:193-198.
13. Johnson MA, Kuo YM, Westaway SK, et al. Mitochondrial localization of PANK2 and hypothesis of secondary iron accumulation in panthotenate-kinase associated neurodegeneration. Ann N Y Acad Sci. 2004;1012:282-298.
14. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57:547-583.
15. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed. 2004;17:433-444.
16. Connor JR. Metals and Oxidative Damage in Neurological Disorders. New York, NY: Plenum Press; 1997.
17. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet. 1999;354:477-479.
18. Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta. 2001;1536:133-140.
19. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583-1587.
20. Franchini M, Veneri D. Iron-chelation therapy: an update. Hematol J. 2004;5:287-292.
21. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-362.
22. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-543.
23. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-3744.
24. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23:1-25.
25. Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep. 2005;4:110-116.
26. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
27. Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G. Purging iron from the heart. Br J Haematol. 2004;125:545-551.
28. Cabantchik ZI, Kakhlon O, Epsztejn S, Zanninelli G, Breuer W. Intracellular and extracellular labile iron pools. Adv Exp Med Biol. 2002;509:55-75.
29. Zanninelli G, Brissot P, Hider RR, Konijn AP, Shanzer A, Cabantchik ZI. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842-852.
30. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792-798.
31. Waldmeier PC, Buchle AM, Steulet AF. Inhibition of catechol-o- methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol. 1993;45:2417-2424.
32. Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Mov Disord. 2005;20:1585-1591.
33. Drayer B, Burger P, Darwin R, Riderer S, Herfkens R, Johnson GA. Magnetic resonance imaging of brain iron. Am J Roentgenol. 1986;147:103-110.
34. Schenck JF. Magnetic resonance imaging of brain iron. J Neurol Sci. 2003;207:99-102.
35. Chen JC, Hardy PA, Clauberg M, et al. T2 values in the human brain: comparison with quantitative assays of iron and ferritin. Radiology. 1989;173:521-526.
36. Bandettini PA, Kwong KK, Davis TL, et al. Characterization of cerebral blood oxygenation and flow changes during prolonged brain activation. Hum Brain Mapp. 1997;5:93-109.
37. Haliwell B, Gutteridge JMC. In: Free Radicals in Biology and Medicine. 3rd ed. Oxford, England: Oxford University Press; 1998:351-429.
38. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005;106:3710-3717.
39. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733-3737.
40. Simon D, Seznec H, Gansmuller A, et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J Neurosci. 2004;24:1987-1995.
41. Wong A, Yang J, Cavadini P, et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet. 1999;8:425-430.
42. Wilson RB, Lynch DR, Fischbeck KH. Normal serum iron and ferritin concentrations in patients with Friedreich's ataxia. Ann Neurol. 1998;44:132-134.
43. Wilson RB. Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006;13:166-175.
44. Muhlenhoff U, Gerber J, Richhardt N, Lill R. Components involved in assembly and dislocation of iron-sulphur clusters on the scaffold protein Isu1p. EMBO J. 2003;22:4815-4825.
45. Grabill C, Silva AC, Smith SS, Koretsky AP, Rouault TA. MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knockout mice. Brain Res. 2003;971:95-106.
46. Geromel V, Darin N, Chretien D, et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab. 2002;77:21-30.
47. Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62:621-626.
48. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106:3242-3250.
49. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood. 1999;94:2128-2134.
50. Jameson GNL, Jameson RF, Linert W. New insights into iron release from ferritin: direct observations of the neurotoxin 6-hydroxydopamine entering ferritin and reaching redox equilibrium with the iron core. Org Biomol Chem. 2004;2:2346-2351.
51. De Domenico I, Vaughn MB, Li L, et al. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome EMBO J. 2006;25:5396-5404.
52. Sturm B, Bistrich U, Schranzhofer M, et al. Friedreich's ataxia: no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts. A decrease in antioxidative capacity? J Biol Chem. 2004;280:6701-6708.
53. Anderson PR, Kirby K, Hilliker AJ, Phillips JP. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet. 2005;14:3397-3405.
54. Cavadini P, Gellera C, Patel PI, Isaya G. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet. 2000;9:2523-2530.
55. Campanella A, Isaya G, O'Neill HA, et al. The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast. Hum Mol Genet. 2004;13:2279-2288.
56. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor DNA1 binding activity: implications for models of hypoxia signal transduction. Blood. 2003;82:3610-3615.
57. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Inv. 2005;35:711-717.
58. Ganz T, Nemeth E. Iron imports, IV: hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290:199-203.
59. Oktay Y, Dioum E, Matsuzaki S, et al. Hypoxiainducible factor 2 alpha regulates expression of the mitochondrial aconitase chaperon protein frataxin. J Biol Chem. 2007;282:11750-11756.